Deferasirox: all 83 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingNCT07023666Phase 2
• Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell TransplantationRecruitingNCT06784336Phase 2
• Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional HemosiderosisCompletedNCT03372083Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedNCT03203850Phase 2Results posted
• Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible TabletCompletedNCT02993224Phase 2Results posted
• Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic SyndromeTerminatedNCT02943668Phase 2Results posted
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) FormulationCompletedNCT02720536Phase 3Results posted
• A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.TerminatedNCT02663752Phase 2Results posted
• Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedNCT02435212Phase 2Results posted
• Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65TerminatedNCT02341495Phase 2Results posted
• Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.TerminatedNCT02159040Phase 2Results posted
• Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia PatientsTerminatedNCT01818726Phase 4Results posted
• Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent ThalassemiaCompletedNCT01709838Phase 4Results posted
• Combination Deferasirox and Deferiprone for Severe Iron Overload in ThalassemiaCompletedNCT01709032Phase 1/2Results posted
• Post Hematopoietic Stem Cell TransplantationCompletedNCT01610297Phase 4Results posted
• Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadTerminatedNCT01459718Phase 2Results posted
• Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability StudyTerminatedNCT01326845Phase 4Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedNCT01254227Phase 2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).CompletedNCT01090323Phase 2Results posted
• Exjade-Early-TrialTerminatedNCT01058369Phase 2Results posted
• Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension StudyCompletedNCT01033747Phase 2/3Results posted
• Clinical Importance of Treating Iron Overload in Sickle Cell DiseaseTerminatedNCT00981370Phase 3Results posted
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy StudyCompletedNCT00940602Phase 2Results posted
• Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron OverloadCompletedNCT00901199Phase 2Results posted
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension StudyCompletedNCT00873041Phase 2Results posted
• Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedNCT00845871Phase 4Results posted
• Pilot Study for Patients With Poor Response to DeferasiroxCompletedNCT00749515Phase 4Results posted
• Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional HemosiderosisCompletedNCT00631163Phase 2Results posted
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 2Results posted
• Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea TardaCompletedNCT00599326Phase 3Results posted
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedNCT00447694Phase 2Results posted
• The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) StudyCompletedNCT00419770Phase 2Results posted
• Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary HemochromatosisCompletedNCT00395629Phase 1/2Results posted
• A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.CompletedNCT00390858Phase 2Results posted
• Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 2Results posted
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3Results posted
• Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 4Results posted
• An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00171210Phase 3Results posted
• Study for the Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00117507Phase 4Results posted
• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 2Results posted
• Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNCT06468423Not applicable
• Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell DiseaseCompletedNCT05392101Phase 2
• Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDSTerminatedNCT03920657Phase 2
• Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to ChelationCompletedNCT03637556Phase 2
• Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA AgentsCompletedNCT03387475Phase 2
• Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia MajorStatus unknownNCT02761395Not applicable
• The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy RegimensStatus unknownNCT02413021Phase 1
• Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)CompletedNCT02233504Early Phase 1
• Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia PatientsCompletedNCT02198508Not applicable
• Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent ThalassemiaWithdrawnNCT02069886Phase 4
• Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02038816Phase 2
• Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High DosesWithdrawnNCT01948817Phase 2
• Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 2
• An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years OldWithdrawnNCT01724138Phase 4
• A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDSStatus unknownNCT01718366Phase 1/2
• Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron OverloadCompletedNCT01369719Not applicable
• Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human EndotoxemiaCompletedNCT01349699Not applicable
• Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron OverloadCompletedNCT01335035Phase 4
• Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea TardaStatus unknownNCT01284946Phase 2
• The Impact of Deferasirox on Non-Alcoholic-SteatohepatitisCompletedNCT01278056Phase 1/2
• This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.CompletedNCT01250951Phase 4
• A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe ToxicityCompletedNCT01044186Phase 2
• Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 MsecCompletedNCT00879242Phase 2
• Iron Balance Study of Deferasirox, Deferoxamine and the Combination of BothStatus unknownNCT00738413Phase 1/2
• Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 4
• Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron OverloadCompletedNCT00654589Phase 4
• Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
• Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00560820Phase 1
• Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadCompletedNCT00481143Phase 4
• Safety, Tolerability, and Efficacy of Deferasirox in MDSCompletedNCT00469560Phase 3
• Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over LoadCompletedNCT00452660Phase 4
• Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.CompletedNCT00432627Phase 1
• Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of MidazolamCompletedNCT00427505Phase 1
• Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy VolunteersCompletedNCT00419172Phase 1
• Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron OverloadCompletedNCT00379483Phase 2
• A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadCompletedNCT00171821Phase 3
• A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisCompletedNCT00171171Phase 3
• Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00067080Phase 2
• Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 2
• Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00061750Phase 3

← Deferasirox overview